Substance Use Disorders Clinical Trial
Official title:
A Randomized Trial of CBT4CBT for Women in Residential Treatment for Substance Use Disorders
Verified date | February 2020 |
Source | Virginia Commonwealth University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This project examines computer-delivered cognitive-behavioral intervention (CBT4CBT) as an adjunct to residential treatment for women with substance use disorders (SUD). The project will conduct a 2-arm randomized clinical trial (RCT) comparing post-discharge relapse rates for treatment as usual (TAU) with access to the CBT4CBT program vs. TAU in a residential sample of women with SUDs.
Status | Completed |
Enrollment | 63 |
Est. completion date | January 18, 2020 |
Est. primary completion date | January 18, 2020 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - =18 years of age - Female - Meet DSM-5 criteria for a SUD (current) - Own a smartphone - Can return to facility for the 4 and 12-week follow-up visits. Exclusion Criteria: - Pregnant - Cognitive or psychiatric impairment - Language barriers that preclude informed consent |
Country | Name | City | State |
---|---|---|---|
United States | Virginia Commonwealth University | Richmond | Virginia |
Lead Sponsor | Collaborator |
---|---|
Virginia Commonwealth University |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Any Relapse | Percent of participants experiencing any relapse (yes/no), defined as any substance use (alcohol or other drugs) by self-report (smartphone or in person) and/or urine drug toxicology or Breathalyzer during 12-week follow-up period. | 12-week follow-up period | |
Primary | Days of Use | Number of days of any substance use in 12 weeks post-discharge. | 12-week follow-up period | |
Secondary | Time to Relapse: | Number of days post discharge to first use of any substance. | 12-week follow-up period |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05660434 -
Using Aromatherapy in Substance Use Disorder
|
N/A | |
Active, not recruiting |
NCT05338268 -
Substance Use and Loneliness
|
N/A | |
Completed |
NCT03954184 -
E-health Implementation (Iowa)
|
N/A | |
Completed |
NCT04098614 -
Barriers to Substance Use Disorder Recovery
|
N/A | |
Completed |
NCT03590106 -
Cardiac Surgery Peer Recovery Support Program
|
N/A | |
Recruiting |
NCT05118204 -
Randomized Trial of Buprenorphine Microdose Inductions During Hospitalization
|
Phase 4 | |
Recruiting |
NCT06273228 -
Parenting Young Children in Pediatrics
|
N/A | |
Recruiting |
NCT05327504 -
Written Exposure Therapy for Veterans With SUD and PTSD
|
N/A | |
Terminated |
NCT03517111 -
The Impact of a Parenting Intervention on Latino Youth Health Behaviors
|
N/A | |
Completed |
NCT04284813 -
Families With Substance Use and Psychosis: A Pilot Study
|
N/A | |
Completed |
NCT04401215 -
Technologically-Augmented Referrals to Mitigate Addiction Consequences
|
N/A | |
Not yet recruiting |
NCT06187701 -
Co-Active Therapeutic Theatre (Co-ATT) for Dual-Diagnosis Patients
|
N/A | |
Not yet recruiting |
NCT06163651 -
Evaluating a One-Year Version of the Parent-Child Assistance Program
|
N/A | |
Recruiting |
NCT04296604 -
Transcranial Direct Current Stimulation (tDCS) Neuromodulation of Executive Function Across Neuropsychiatric Populations
|
N/A | |
Active, not recruiting |
NCT02382042 -
Intensive Referral Intervention to Improve Substance Use Disorder Treatment Outcomes Among Rural and Highly Rural Veterans
|
N/A | |
Terminated |
NCT01356667 -
Drum-Assisted Therapy for Native Americans
|
N/A | |
Completed |
NCT01237366 -
Study Targeting Affect Regulation
|
Phase 1/Phase 2 | |
Completed |
NCT00708890 -
Twelve Step Based Self-help Groups for Substance Related Disorders
|
N/A | |
Active, not recruiting |
NCT04048850 -
Zepatier in Patients With Substance Use
|
||
Recruiting |
NCT05976646 -
Phase Ib/2a Drug-drug Interaction Study of a Combination of 45mg Dextromethorphan With 105 mg Bupropion
|
Phase 1/Phase 2 |